US Patent

US9662394 — Stabilized efinaconazole compositions

Formulation · Assigned to Dow Pharmaceutical Sciences Inc · Expires 2034-10-02 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects stabilized compositions containing efinaconazole, butylated hydroxytoluene, and a salt of ethylenediaminetetraacetic acid.

USPTO Abstract

The present invention provides compositions containing efinaconazole, butylated hydroxytoluene, a salt of ethylenediaminetetraacetic acid, and optional citric acid. The compositions exhibit stable color profiles and are useful in the treatment of fungal infections.

Drugs covered by this patent

Patent Metadata

Patent number
US9662394
Jurisdiction
US
Classification
Formulation
Expires
2034-10-02
Drug substance claim
No
Drug product claim
Yes
Assignee
Dow Pharmaceutical Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.